Alexandria Real Estate Equities (ARE) Q2 2026 earnings review
Leasing Rebounds, But Impairments and Leverage Toll the Bottom Line
Alexandria printed $1.73 in Adjusted FFO per share—flat sequentially but down 26% YoY, driven by aggressive asset sales, a sharp drop in occupancy to 86.9%, and $222 million in real estate impairments. However, demand showed signs of life: leasing volume surged past 1 million square feet (up 60% QoQ), and rent roll-downs moderated significantly. The company is leaning entirely on its $2.9 billion disposition plan to reduce a swollen 7.0x leverage ratio back to its 5.6x-6.2x target by year-end, signaling that survival and balance sheet defense continue to outweigh organic growth.
🐂 Bull Case
Total leasing exceeded 1 million RSF, outperforming the prior four-quarter average. The successful pivot to 'advanced technology' tenants proves the portfolio's versatility beyond traditional life sciences.
While current occupancy sits at 86.9%, there is an embedded 4.0% future benefit from 1.4 million RSF of leased space that is not yet occupied, signaling a contracted revenue recovery in 2027.
🐻 Bear Case
Net debt and preferred stock to Adjusted EBITDA ballooned to 7.0x on an annualized basis. Hitting the 5.6x-6.2x year-end target requires flawless execution of an aggressive disposition pipeline in a tough market.
Same-property NOI dropped 10.6% YoY. Management is struggling to replace high-paying biotech expirations without sacrificing rental rates or tolerating extensive downtime.
⚖️ Verdict: 🔴
Bearish. While the sequential stabilization in FFO and the spike in leasing volume are positive early indicators, the actual financials reflect deep structural pain. A 7.0x leverage ratio, massive impairment charges, and contracting organic income mean the turnaround is still quarters away.
Key Themes
Leasing Volume vs. NOI Contradiction
A severe contradiction exists between the topline narrative and bottom-line reality. Leasing volume accelerated 60% QoQ to 1.04 million RSF. However, this is heavily contradicted by a 10.6% plunge in Same Property NOI. The new leases are merely backfilling massive structural move-outs (260k RSF of known vacates in Q2), mostly at negative rent spreads (-0.7%), failing to translate leasing volume into organic profit growth.
Pivoting to Advanced Technology
To counter the sluggish public biotech market (Macro concern), Alexandria is actively shifting asset uses. In Q2, they executed a 160k RSF lease at the 3000 Minuteman Road redevelopment, pivoting from laboratory space to 'advanced technology'. This strategic product innovation avoids heavy lab CapEx, cuts the project budget by $80M, and generates faster revenue, proving the underlying real estate is attractive beyond life sciences.
Massive Impairments to Clear the Decks
The company recorded a stunning $222.5M impairment charge in Q2 to write down assets held for sale. This included $64M for land in Sorrento Mesa (selling to a residential developer), $61M for a Canadian property, and $24M for a Cambridge office. This highlights the brutal reality of liquidating unviable life science developments to raise defensive capital.
Leverage Spikes While Awaiting Sales
Net debt and preferred stock to Adjusted EBITDA spiked to 7.0x (annualized) in Q2, severely above the company's 4Q26 target of 5.6x to 6.2x. Fixing this relies entirely on executing the remaining $2.7B of their $2.9B disposition goal. As of early August, $1.16B was pending or under LOI, leaving significant execution risk in H2.
G&A Austerity Defending Margins
Management continues to aggressively strip out corporate overhead. General and administrative expenses fell 17.4% YoY. Trailing 12-month G&A is running at just 6.6% of NOI—roughly half the S&P 500 REIT average. The company remains on track for $76M in cumulative G&A savings across 2025 and 2026.
Megacampus Platform Anchors the Ship
Despite widespread market weakness, Alexandria's Megacampus ecosystems continue to outperform, accounting for 80% of annual rental revenue. In their top three markets (Boston, SF, San Diego), Alexandria's occupancy runs 8.4% to 11.7% higher than the broader market average, verifying the "flight to quality" thesis.
Other KPIs
Reversing. Alexandria printed a net loss of $73.7M, compared to net income of $358.9M in Q1, entirely driven by the $222.5M real estate impairment charge recognized during the quarter.
Accelerating/Stabilizing. Rent roll-downs were virtually flat at -0.7% on renewals and re-leasing, representing a massive sequential improvement from the draconian -15.0% GAAP and -15.8% Cash spreads seen in Q1. This suggests leasing panic is subsiding.
Stable. Bolstered by the extension of their $5.0 billion unsecured line of credit to 2032. Only 6% of total debt matures through 2028, insulating the company from immediate refinancing shocks.
Guidance
Stable sequentially, but Decelerating severely YoY. The midpoint of $6.40 was maintained (range narrowed). Compared to the FY25 actual of $9.01, this represents a ~29% earnings contraction as capitalization of interest burns off and assets are sold.
Stable. Midpoint of -9.5% remains unchanged. Driven by the mathematical reality of known 2026 lease expirations and the time required to build out spaces for new tenants.
Stable. The year-end midpoint target of 87.0% indicates that the sequential occupancy bleeding (down 80 bps in Q2) is expected to plateau in the second half of the year as the 1.4M RSF backlog of signed leases commences.
Accelerating/Improving. The current level sits at a highly elevated 7.0x. Achieving this rapid deleveraging is entirely dependent on closing $1.675 billion in debt reduction funded by asset dispositions in H2 2026.
Key Questions
Advanced Tech Yields vs Life Science
The pivot to 'advanced technology' at 3000 Minuteman Road saved $80M in CapEx but comes with lower rents. How do the stabilized cash yields on these advanced tech deals compare to traditional Class A life science lab developments?
Impairment Floor
With $222M in Q2 impairments following the massive $1.45B hit in late 2025, how much of the current land and non-core operating portfolio is still held at values significantly above what the transactional market will bear today?
Leverage Contingency Plan
Leverage spiked to 7.0x this quarter. If the $1.16B in pending/LOI dispositions stall due to capital market jitters, what is the contingency plan to defend the balance sheet and avoid a credit rating downgrade?
Visibility into 2027 Expirations
Management flagged an embedded +4.0% occupancy benefit from signed leases, but 2027 brings another massive wave of lease expirations. What percentage of 2027 rollovers are currently at high risk for move-outs or severe rent roll-downs?